Connect Biopharma Holdings Limited
CNTB
$2.55
$0.010.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5,666.67% | -- | -100.00% | -98.69% | -99.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,666.67% | -- | -100.00% | -98.69% | -99.80% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5,666.67% | -- | -100.00% | -98.69% | -99.80% |
| SG&A Expenses | -12.77% | -1.41% | 3.99% | 32.83% | 6.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.22% | 72.76% | 50.49% | 33.38% | 48.53% |
| Operating Income | -31.14% | -71.29% | -61.41% | -46.75% | -189.22% |
| Income Before Tax | -34.10% | -89.37% | -71.39% | -33.70% | -186.33% |
| Income Tax Expenses | 9.09% | -11.11% | -74.53% | 7.02% | 83.33% |
| Earnings from Continuing Operations | -33.99% | -88.84% | -69.65% | -33.58% | -186.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.99% | -88.84% | -69.65% | -33.58% | -186.88% |
| EBIT | -31.14% | -71.29% | -61.41% | -46.75% | -189.22% |
| EBITDA | -31.62% | -72.46% | -62.19% | -47.41% | -187.14% |
| EPS Basic | -18.29% | -84.86% | -67.39% | -32.49% | -186.39% |
| Normalized Basic EPS | -18.40% | -85.36% | -69.11% | -54.33% | -178.46% |
| EPS Diluted | -18.29% | -84.86% | -67.39% | -32.49% | -186.39% |
| Normalized Diluted EPS | -18.40% | -85.36% | -69.11% | -54.33% | -179.19% |
| Average Basic Shares Outstanding | 13.31% | 2.16% | 1.37% | 0.84% | 0.57% |
| Average Diluted Shares Outstanding | 13.31% | 2.16% | 1.37% | 0.84% | -0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |